Concepts (276)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 33 | 2020 | 195 | 5.200 |
Why?
|
| Infection Control | 22 | 2020 | 101 | 3.750 |
Why?
|
| Staphylococcal Infections | 18 | 2016 | 156 | 3.470 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 11 | 2017 | 92 | 2.080 |
Why?
|
| Copper | 6 | 2017 | 149 | 1.810 |
Why?
|
| Bacteremia | 8 | 2016 | 155 | 1.680 |
Why?
|
| Methicillin Resistance | 9 | 2008 | 45 | 1.680 |
Why?
|
| Disinfectants | 4 | 2013 | 61 | 1.620 |
Why?
|
| Vancomycin Resistance | 9 | 2013 | 18 | 1.600 |
Why?
|
| Staphylococcus aureus | 9 | 2012 | 175 | 1.600 |
Why?
|
| Disinfection | 7 | 2017 | 112 | 1.590 |
Why?
|
| Carrier State | 6 | 2016 | 39 | 1.430 |
Why?
|
| Enterococcus | 7 | 2013 | 29 | 1.350 |
Why?
|
| Anti-Bacterial Agents | 17 | 2018 | 1026 | 1.270 |
Why?
|
| Intensive Care Units | 6 | 2014 | 344 | 1.230 |
Why?
|
| Gram-Positive Bacterial Infections | 7 | 2013 | 35 | 1.180 |
Why?
|
| Hospitals | 15 | 2021 | 265 | 1.180 |
Why?
|
| Environmental Microbiology | 3 | 2013 | 25 | 0.900 |
Why?
|
| Fomites | 2 | 2013 | 12 | 0.890 |
Why?
|
| Influenza Vaccines | 3 | 2013 | 56 | 0.860 |
Why?
|
| Influenza, Human | 3 | 2013 | 79 | 0.850 |
Why?
|
| Operating Rooms | 2 | 2020 | 108 | 0.810 |
Why?
|
| Bacterial Infections | 4 | 2013 | 163 | 0.760 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 27 | 0.710 |
Why?
|
| Clinical Protocols | 1 | 2020 | 172 | 0.680 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2010 | 98 | 0.650 |
Why?
|
| Humans | 70 | 2021 | 68618 | 0.630 |
Why?
|
| Vaccination | 2 | 2013 | 189 | 0.580 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 143 | 0.580 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 154 | 0.580 |
Why?
|
| Catheterization, Central Venous | 4 | 2018 | 89 | 0.580 |
Why?
|
| Health Personnel | 3 | 2021 | 286 | 0.560 |
Why?
|
| Pandemics | 1 | 2020 | 352 | 0.550 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2011 | 245 | 0.550 |
Why?
|
| Beds | 2 | 2013 | 13 | 0.540 |
Why?
|
| Bacterial Load | 2 | 2013 | 24 | 0.540 |
Why?
|
| Mycobacterium Infections | 1 | 2016 | 13 | 0.540 |
Why?
|
| Disease Outbreaks | 4 | 2012 | 83 | 0.530 |
Why?
|
| Prosthesis-Related Infections | 3 | 2014 | 70 | 0.500 |
Why?
|
| Colony Count, Microbial | 5 | 2018 | 77 | 0.490 |
Why?
|
| Critical Care | 6 | 2014 | 263 | 0.480 |
Why?
|
| Nursing Staff, Hospital | 2 | 2007 | 62 | 0.470 |
Why?
|
| Clostridium Infections | 3 | 2020 | 52 | 0.470 |
Why?
|
| Community-Acquired Infections | 3 | 2011 | 46 | 0.460 |
Why?
|
| Gram-Negative Bacterial Infections | 3 | 2009 | 62 | 0.430 |
Why?
|
| Mycoses | 1 | 2013 | 60 | 0.430 |
Why?
|
| Drug Utilization | 2 | 2010 | 119 | 0.420 |
Why?
|
| Gram-Negative Bacteria | 4 | 2017 | 55 | 0.420 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2010 | 85 | 0.410 |
Why?
|
| Hospitals, Special | 2 | 2014 | 15 | 0.410 |
Why?
|
| Neutropenia | 2 | 2011 | 72 | 0.410 |
Why?
|
| Attitude of Health Personnel | 2 | 2013 | 442 | 0.400 |
Why?
|
| Bacteria | 4 | 2015 | 193 | 0.400 |
Why?
|
| Obstetric Labor, Premature | 1 | 2012 | 76 | 0.390 |
Why?
|
| Staphylococcal Skin Infections | 2 | 2012 | 14 | 0.380 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2012 | 92 | 0.380 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 5 | 2017 | 47 | 0.360 |
Why?
|
| Enterobacteriaceae | 1 | 2010 | 29 | 0.360 |
Why?
|
| Nasal Cavity | 1 | 2010 | 62 | 0.340 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2013 | 767 | 0.340 |
Why?
|
| Retroviridae Infections | 1 | 2009 | 7 | 0.340 |
Why?
|
| Retroviridae | 1 | 2009 | 29 | 0.340 |
Why?
|
| Bioterrorism | 1 | 2009 | 12 | 0.340 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2010 | 133 | 0.340 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2009 | 14 | 0.330 |
Why?
|
| Population Surveillance | 2 | 2010 | 285 | 0.330 |
Why?
|
| Strongyloides | 1 | 2008 | 2 | 0.330 |
Why?
|
| Antinematodal Agents | 1 | 2008 | 4 | 0.320 |
Why?
|
| Strongyloidiasis | 1 | 2008 | 5 | 0.320 |
Why?
|
| Ivermectin | 1 | 2008 | 12 | 0.320 |
Why?
|
| Sentinel Surveillance | 3 | 2020 | 20 | 0.320 |
Why?
|
| Catheters, Indwelling | 2 | 2011 | 72 | 0.310 |
Why?
|
| Vancomycin | 2 | 2008 | 60 | 0.310 |
Why?
|
| Anti-Infective Agents | 4 | 2018 | 166 | 0.300 |
Why?
|
| Long-Term Care | 1 | 2007 | 53 | 0.290 |
Why?
|
| Knee Prosthesis | 1 | 2007 | 64 | 0.290 |
Why?
|
| Veterinary Drugs | 2 | 2017 | 8 | 0.280 |
Why?
|
| Hip Prosthesis | 1 | 2007 | 85 | 0.280 |
Why?
|
| Male | 18 | 2018 | 37321 | 0.270 |
Why?
|
| Catheter-Related Infections | 3 | 2018 | 43 | 0.270 |
Why?
|
| Hospitals, Community | 1 | 2006 | 64 | 0.260 |
Why?
|
| Culture Media | 1 | 2006 | 155 | 0.260 |
Why?
|
| Middle Aged | 12 | 2018 | 21147 | 0.250 |
Why?
|
| Personnel, Hospital | 1 | 2004 | 19 | 0.250 |
Why?
|
| Immunization Programs | 1 | 2004 | 25 | 0.240 |
Why?
|
| Virginia | 4 | 2006 | 45 | 0.240 |
Why?
|
| Patients' Rooms | 2 | 2015 | 15 | 0.240 |
Why?
|
| Female | 15 | 2018 | 38074 | 0.240 |
Why?
|
| Surgical Wound Infection | 3 | 2018 | 168 | 0.230 |
Why?
|
| Adult | 12 | 2016 | 21403 | 0.230 |
Why?
|
| South Carolina | 7 | 2020 | 2752 | 0.230 |
Why?
|
| Incidence | 5 | 2013 | 1603 | 0.210 |
Why?
|
| Risk Factors | 8 | 2018 | 5731 | 0.210 |
Why?
|
| Mass Screening | 1 | 2008 | 843 | 0.210 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2002 | 54 | 0.200 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 3 | 2012 | 23 | 0.190 |
Why?
|
| Soft Tissue Infections | 2 | 2012 | 19 | 0.190 |
Why?
|
| Drug Resistance, Microbial | 2 | 2016 | 70 | 0.190 |
Why?
|
| Myelitis, Transverse | 1 | 2000 | 2 | 0.180 |
Why?
|
| Bartonella henselae | 1 | 2000 | 9 | 0.180 |
Why?
|
| Cat-Scratch Disease | 1 | 2000 | 10 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2004 | 468 | 0.180 |
Why?
|
| Antibodies, Bacterial | 1 | 2000 | 90 | 0.180 |
Why?
|
| Length of Stay | 3 | 2009 | 780 | 0.170 |
Why?
|
| Alloys | 2 | 2017 | 66 | 0.170 |
Why?
|
| Inpatients | 1 | 2021 | 208 | 0.170 |
Why?
|
| Multivariate Analysis | 3 | 2008 | 1046 | 0.170 |
Why?
|
| Prospective Studies | 4 | 2017 | 3705 | 0.170 |
Why?
|
| HIV Infections | 2 | 2009 | 791 | 0.170 |
Why?
|
| Betacoronavirus | 1 | 2020 | 116 | 0.160 |
Why?
|
| Hospital Costs | 2 | 2009 | 117 | 0.160 |
Why?
|
| Patient Care Team | 1 | 2020 | 311 | 0.150 |
Why?
|
| Program Evaluation | 1 | 2020 | 502 | 0.150 |
Why?
|
| Hospitals, University | 2 | 2010 | 169 | 0.150 |
Why?
|
| Patient Isolation | 2 | 2009 | 35 | 0.150 |
Why?
|
| Stethoscopes | 1 | 2017 | 4 | 0.150 |
Why?
|
| Salmonella Food Poisoning | 1 | 2017 | 4 | 0.140 |
Why?
|
| Intention to Treat Analysis | 2 | 2015 | 38 | 0.140 |
Why?
|
| Campylobacter Infections | 1 | 2016 | 7 | 0.140 |
Why?
|
| Animals, Domestic | 1 | 2016 | 8 | 0.140 |
Why?
|
| Foodborne Diseases | 1 | 2016 | 14 | 0.140 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2015 | 226 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 445 | 0.140 |
Why?
|
| Actinomyces | 1 | 2016 | 3 | 0.140 |
Why?
|
| Actinomycosis | 1 | 2016 | 6 | 0.140 |
Why?
|
| Mycobacterium fortuitum | 1 | 2016 | 3 | 0.140 |
Why?
|
| Prevalence | 4 | 2011 | 1619 | 0.140 |
Why?
|
| Mycobacterium chelonae | 1 | 2016 | 9 | 0.140 |
Why?
|
| Aged | 7 | 2016 | 14862 | 0.140 |
Why?
|
| Retrospective Studies | 6 | 2018 | 7277 | 0.130 |
Why?
|
| Sepsis | 1 | 2018 | 233 | 0.130 |
Why?
|
| Environment Design | 1 | 2015 | 40 | 0.130 |
Why?
|
| Logistic Models | 3 | 2010 | 1420 | 0.120 |
Why?
|
| Infant, Newborn | 4 | 2014 | 2455 | 0.120 |
Why?
|
| Arthritis, Infectious | 1 | 2014 | 14 | 0.120 |
Why?
|
| Nose | 2 | 2011 | 36 | 0.110 |
Why?
|
| Young Adult | 4 | 2016 | 5717 | 0.110 |
Why?
|
| Arthroplasty, Replacement | 1 | 2014 | 48 | 0.110 |
Why?
|
| Virulence Factors | 1 | 2012 | 11 | 0.110 |
Why?
|
| Pneumonia, Ventilator-Associated | 2 | 2014 | 31 | 0.110 |
Why?
|
| Dengue Virus | 1 | 2012 | 3 | 0.110 |
Why?
|
| Dengue | 1 | 2012 | 5 | 0.110 |
Why?
|
| Administration, Oral | 3 | 2014 | 411 | 0.110 |
Why?
|
| Child | 7 | 2016 | 6405 | 0.110 |
Why?
|
| Hepatitis | 1 | 2012 | 25 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 772 | 0.100 |
Why?
|
| Klebsiella Infections | 1 | 2012 | 13 | 0.100 |
Why?
|
| Klebsiella pneumoniae | 1 | 2012 | 18 | 0.100 |
Why?
|
| Pneumonia, Bacterial | 1 | 2012 | 19 | 0.100 |
Why?
|
| beta-Lactamases | 1 | 2012 | 33 | 0.100 |
Why?
|
| United States | 5 | 2017 | 7367 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2012 | 35 | 0.100 |
Why?
|
| Emergency Medical Services | 1 | 2014 | 225 | 0.100 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 4848 | 0.100 |
Why?
|
| Nasal Mucosa | 1 | 2011 | 68 | 0.100 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2012 | 113 | 0.090 |
Why?
|
| Child, Preschool | 5 | 2016 | 3187 | 0.090 |
Why?
|
| Gestational Age | 1 | 2012 | 389 | 0.090 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2010 | 25 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1553 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2016 | 2358 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 83 | 0.090 |
Why?
|
| Infant, Premature | 1 | 2012 | 284 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2010 | 98 | 0.090 |
Why?
|
| Anti-Retroviral Agents | 1 | 2010 | 53 | 0.080 |
Why?
|
| Pseudomonas Infections | 1 | 2010 | 83 | 0.080 |
Why?
|
| Viral Load | 1 | 2010 | 127 | 0.080 |
Why?
|
| Hand Disinfection | 1 | 2009 | 9 | 0.080 |
Why?
|
| Sanitation | 1 | 2009 | 5 | 0.080 |
Why?
|
| Outpatients | 1 | 2010 | 127 | 0.080 |
Why?
|
| Bacterial Toxins | 1 | 2009 | 50 | 0.080 |
Why?
|
| Ileum | 1 | 2008 | 28 | 0.080 |
Why?
|
| Urinary Catheterization | 1 | 2008 | 27 | 0.080 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 55 | 0.080 |
Why?
|
| Disease Susceptibility | 1 | 2009 | 179 | 0.080 |
Why?
|
| Time Factors | 1 | 2016 | 4655 | 0.080 |
Why?
|
| Urinary Tract Infections | 1 | 2008 | 71 | 0.080 |
Why?
|
| China | 3 | 2012 | 138 | 0.080 |
Why?
|
| Patient Admission | 1 | 2008 | 99 | 0.070 |
Why?
|
| Respiration, Artificial | 1 | 2008 | 190 | 0.070 |
Why?
|
| Needlestick Injuries | 1 | 2007 | 10 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2011 | 1342 | 0.070 |
Why?
|
| Risk | 1 | 2008 | 563 | 0.070 |
Why?
|
| Education, Nursing, Continuing | 1 | 2007 | 27 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 2279 | 0.070 |
Why?
|
| Denmark | 2 | 2017 | 24 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2007 | 216 | 0.070 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 281 | 0.070 |
Why?
|
| Canada | 2 | 2017 | 267 | 0.070 |
Why?
|
| Pregnancy | 1 | 2012 | 2334 | 0.070 |
Why?
|
| Cattle | 2 | 2017 | 475 | 0.070 |
Why?
|
| Comorbidity | 1 | 2010 | 1426 | 0.060 |
Why?
|
| Swine | 2 | 2017 | 672 | 0.060 |
Why?
|
| Health Care Costs | 2 | 2008 | 346 | 0.060 |
Why?
|
| Infant | 4 | 2016 | 2891 | 0.060 |
Why?
|
| Hospitals, Teaching | 1 | 2004 | 65 | 0.060 |
Why?
|
| Morbidity | 1 | 2003 | 130 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2003 | 57 | 0.050 |
Why?
|
| Molecular Typing | 2 | 2012 | 5 | 0.050 |
Why?
|
| Adolescent | 4 | 2016 | 8912 | 0.050 |
Why?
|
| Zanamivir | 1 | 2002 | 2 | 0.050 |
Why?
|
| Rimantadine | 1 | 2002 | 3 | 0.050 |
Why?
|
| Oseltamivir | 1 | 2002 | 6 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2002 | 95 | 0.050 |
Why?
|
| Pyrans | 1 | 2002 | 16 | 0.050 |
Why?
|
| Amantadine | 1 | 2002 | 8 | 0.050 |
Why?
|
| Sialic Acids | 1 | 2002 | 27 | 0.050 |
Why?
|
| Guanidines | 1 | 2002 | 32 | 0.050 |
Why?
|
| Acetamides | 1 | 2002 | 17 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 196 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2004 | 402 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2008 | 2007 | 0.050 |
Why?
|
| Occupational Exposure | 1 | 2002 | 122 | 0.050 |
Why?
|
| DNA, Bacterial | 2 | 2012 | 150 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2001 | 34 | 0.050 |
Why?
|
| Fever | 1 | 2001 | 96 | 0.050 |
Why?
|
| Recurrence | 1 | 2003 | 948 | 0.050 |
Why?
|
| Animals | 3 | 2017 | 20881 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2002 | 211 | 0.040 |
Why?
|
| Hospitals, Veterans | 1 | 2020 | 147 | 0.040 |
Why?
|
| Bias | 1 | 2020 | 148 | 0.040 |
Why?
|
| Prognosis | 1 | 2003 | 2093 | 0.040 |
Why?
|
| Air Microbiology | 1 | 2018 | 8 | 0.040 |
Why?
|
| Data Collection | 1 | 2020 | 420 | 0.040 |
Why?
|
| Risk Management | 1 | 2018 | 37 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 1753 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 1851 | 0.040 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2017 | 6 | 0.040 |
Why?
|
| Poultry | 1 | 2017 | 14 | 0.040 |
Why?
|
| Red Meat | 1 | 2017 | 10 | 0.040 |
Why?
|
| Food Microbiology | 1 | 2017 | 24 | 0.040 |
Why?
|
| Salmonella | 1 | 2017 | 20 | 0.040 |
Why?
|
| Campylobacter | 1 | 2016 | 5 | 0.040 |
Why?
|
| Turkeys | 1 | 2016 | 16 | 0.040 |
Why?
|
| Food Contamination | 1 | 2017 | 56 | 0.040 |
Why?
|
| Equipment Contamination | 1 | 2017 | 38 | 0.040 |
Why?
|
| Agriculture | 1 | 2017 | 54 | 0.040 |
Why?
|
| Animal Feed | 1 | 2016 | 52 | 0.030 |
Why?
|
| Macrolides | 1 | 2016 | 48 | 0.030 |
Why?
|
| Meat | 1 | 2016 | 34 | 0.030 |
Why?
|
| Milk | 1 | 2016 | 43 | 0.030 |
Why?
|
| Feces | 1 | 2016 | 88 | 0.030 |
Why?
|
| Chickens | 1 | 2017 | 232 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2016 | 123 | 0.030 |
Why?
|
| Hand Hygiene | 1 | 2014 | 1 | 0.030 |
Why?
|
| Organ Transplantation | 1 | 2016 | 110 | 0.030 |
Why?
|
| Disease Transmission, Infectious | 1 | 2014 | 25 | 0.030 |
Why?
|
| Debridement | 1 | 2014 | 55 | 0.030 |
Why?
|
| Ecuador | 1 | 2012 | 8 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2012 | 207 | 0.030 |
Why?
|
| Travel | 1 | 2012 | 38 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2012 | 16 | 0.030 |
Why?
|
| Genes, Bacterial | 1 | 2012 | 40 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2012 | 114 | 0.030 |
Why?
|
| Intensive Care, Neonatal | 1 | 2012 | 38 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2014 | 287 | 0.030 |
Why?
|
| Staphylococcal Protein A | 1 | 2011 | 15 | 0.020 |
Why?
|
| Axilla | 1 | 2011 | 36 | 0.020 |
Why?
|
| Bacterial Typing Techniques | 1 | 2011 | 19 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2003 | 7029 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 219 | 0.020 |
Why?
|
| Plasmids | 1 | 2012 | 258 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2012 | 245 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 492 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2011 | 174 | 0.020 |
Why?
|
| Neoplasms | 1 | 2001 | 1667 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 786 | 0.020 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2011 | 161 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2011 | 340 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2008 | 124 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 1040 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 438 | 0.020 |
Why?
|
| Age Factors | 1 | 2009 | 1864 | 0.020 |
Why?
|
| Hypotension | 1 | 2001 | 74 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2001 | 180 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2001 | 1070 | 0.010 |
Why?
|